

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5





Fig. 6 A






Fig. 7




Fig. 8




Fig. 9








Fig. 10A

Figure 10b  
Pressure-Volume CurvesFigure 10c  
Changes in PMN and Lymphocyte Counts




INTRAVENOUS

Fig. 11




INTRACRANIAL

Fig. 12




SYSTEMIC

Fig. 13




INTAKE Level 1

Fig. 14



INTAKE Level 2

Fig. 15



HIGH EXPOSURE

Fig. 16

## Format A: Immunodetection




Fig. 17A

## Format B: Competitive binding





Fig. 17B

# Human Fibronectin Protopomer



## Binding of CC10 to Fn Fragments




Fig. 19

Figure 20

Titration of rhUG Binding to Fibronectin and Its Fragments




Fig. 20A

Nanograms of rhUG




Fig. 20B

Nanograms of rhUG




Figure 22

## TNF-alpha in BAL





Figure 24 •  
Maturation of Hemopoietic Stem Cells



**Figure 25**  
**ATPase Activity in CD71-positive Cells**




Figure 26  
ATPase Activity in CD11b-positive Cells








FIG 2

VEGF-A (100 pg/ml) + 200 nM U.G. IN 5% SERUM	VEGF-A (100 pg/ml) IN 5% SERUM (CONTROL)
--	--



Time 20 hours




Time 40 hours




Time 60 hours



**Figure 29**  
**Inhibition of endothelial cell migration by rhUG**




**Figure 30**  
**Matrigel invasion by HMEC**



Double asterisk indicates significant differences with VEGF alone or CC10 alone.  
Triple asterisk indicates significant differences with all other treatments

**Figure 31A**  
**Growth Curve for HMVEC**



U.G. dose-dependent HMVEC-D response to high dose VEGF-A stimulation  
at hs. 96 in 1.5% serum





FIG 31 B

Figure 32  
Proteins in Hfl-1, A549 and Hec-1A cells that  
are recognized by anti-Fn monoclonal  
antibody



Western blot probed with anti-human fibronectin monoclonal antibody:  
Lane 1- Rainbow marker; 2- Hfl-1 extract; 5- A549 extract; 9- Hec-1A extract





Figure 33

A549 soft agar assay, plate 2, 25 days  
First row: control, second row: 0.2  $\mu$ M rhUG treated cells  
No. of living cells or very small colonies (No. of well shaped colonies) in each well

255 (109)	240 (98)	293 (120)
57 (25)	89 (44)	97 (52)

FIG. 33

Figure 34



Silver-stained SDS-PAGE gel: lane 1 - Rainbow marker; lane 2 - membrane protein extract from Hec-1A eluted from UG affinity column. Arrows indicate the protein bands that were recognized by anti-CD148 anti-sera.